Identifying Rational Candidates for Immunotherapy _targeting PD-1/PD-L1 in Cervical Cancer
- PMID: 28870938
- DOI: 10.21873/anticanres.11926
Identifying Rational Candidates for Immunotherapy _targeting PD-1/PD-L1 in Cervical Cancer
Abstract
Background/aim: To investigate the abundance of programmed death-ligand 1 (PD-L1) expression and identify rational candidates for anti-PD-1/PD-L1 immunotherapies in cervical cancer.
Patients and methods: In 27 patients with FIGO stage IB1-IIA cervical cancer, paraffin-embedded tumors were immunohistochemically stained with PD-L1 antibody. The correlation of tumoral PD-L1 expression with clinicopathological factors and survival outcomes were evaluated.
Results: Overall, PD-L1 expression was primarily detected in 12 (44.4%) patients. All tumors with PD-L1 expression were squamous cell carcinomas (SqCC). In subgroup analysis of SqCC, higher PD-L1 expression was associated with low preoperative serum SqCC antigen level (p=0.030) and no parametrial invasion (p=0.048). The 5-year progression-free survival (83.3% vs. 50.0%. p=0.136) and overall survival rates (90.9% vs. 83.3%, p=0.615) were superior in patients with PD-L1 expression that in those without PD-L1 expression; however, neither was significant.
Conclusion: Patients with SqCC and favorable clinicopathological factors could be candidates for anti-PD-1/PD-L1 immunotherapy in cervical cancer.
Keywords: Programmed death-ligand 1; cervical cancer; immunohistochemistry; squamous cell carcinoma.
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.Lung Cancer. 2015 Apr;88(1):24-33. doi: 10.1016/j.lungcan.2015.01.016. Epub 2015 Jan 24. Lung Cancer. 2015. PMID: 25662388
-
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015. PLoS One. 2015. PMID: 26313362 Free PMC article.
-
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.Eur J Cancer. 2016 Apr;57:91-103. doi: 10.1016/j.ejca.2015.12.033. Epub 2016 Feb 21. Eur J Cancer. 2016. PMID: 26901614
-
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.JAMA Oncol. 2016 Sep 1;2(9):1217-22. doi: 10.1001/jamaoncol.2016.0639. JAMA Oncol. 2016. PMID: 27310809 Review.
-
Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer.Biomed Pharmacother. 2023 Oct;166:115355. doi: 10.1016/j.biopha.2023.115355. Epub 2023 Aug 28. Biomed Pharmacother. 2023. PMID: 37647692 Review.
Cited by
-
Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data.Front Oncol. 2022 Dec 22;12:1045481. doi: 10.3389/fonc.2022.1045481. eCollection 2022. Front Oncol. 2022. PMID: 36644634 Free PMC article. Review.
-
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.Front Oncol. 2021 Feb 1;10:572203. doi: 10.3389/fonc.2020.572203. eCollection 2020. Front Oncol. 2021. PMID: 33634012 Free PMC article.
-
Concordance Study Between IBM Watson for Oncology and Real Clinical Practice for Cervical Cancer Patients in China: A Retrospective Analysis.Front Genet. 2020 Mar 24;11:200. doi: 10.3389/fgene.2020.00200. eCollection 2020. Front Genet. 2020. PMID: 32265980 Free PMC article.
-
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.Cancer Cell Int. 2019 May 23;19:146. doi: 10.1186/s12935-019-0861-7. eCollection 2019. Cancer Cell Int. 2019. PMID: 31143091 Free PMC article.
-
The Role of Epstein-Barr Virus in Cervical Cancer: A Brief Update.Front Oncol. 2018 Apr 17;8:113. doi: 10.3389/fonc.2018.00113. eCollection 2018. Front Oncol. 2018. PMID: 29719817 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
